The effect of udenafil on the hemodynamics of healthy male volunteers administered tamsulosin

References

• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
   PubMed Web of Science ®Google Scholar
• Rosen RC. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006;16:11-19
   PubMed Web of Science ®Google Scholar
• Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824-37
   PubMed Web of Science ®Google Scholar
• Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int 2003;91:196-200
   PubMed Web of Science ®Google Scholar
• Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172(5 Pt 1):1935-40
   Web of Science ®Google Scholar
• Viagra oral tablets, sildenafil citrate oral tablets. Pfizer Inc., 2011. Available at: http://www.pfizer.com/files/products/uspi_viagra.pdf [Last accessed 23 December 2012]
   Google Scholar
• Flomax (tamsulosin hydrochloride) capsules. Astellas Pharma Inc., 2009. Available at: http://www.astellas.us/docs/Flomax.pdf [Last accessed 23 December 2012]
   Google Scholar
• Cialis (tadalafil) oral tablets. Eli Lilly and Company, 2011. Available at: http://pi.lilly.com/us/cialis-pi.pdf [Last accessed 23 December 2012]
   Google Scholar
• Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008;65:848-54
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:380-7
   PubMed Web of Science ®Google Scholar
• Zydena (udenafil) tablets. Dong-A ST, 2013. Available at: http://www.kimsonline.co.kr [Last accessed 31 March 2013]
   Google Scholar
• Ji HY, Lee HW, Kim HH, et al. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica 2004;34:973-82
   PubMed Web of Science ®Google Scholar
• Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2009;68:43-6
   PubMed Web of Science ®Google Scholar
• Choi SJ, Ji HY, Lee HY, et al. In vitro metabolism of a novel phosphodiesterase-5 inhibitor DA-8159 in rat liver preparations using liquid chromatography/electrospray mass spectrometry. Biomed Chrom 2002;16:395-9
   PubMed Web of Science ®Google Scholar
• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161:46-8
   PubMed Web of Science ®Google Scholar
• Julious SA. Sample sizes for clinical trials with normal data. Stat Med 2004;23:1921-86
   PubMed Web of Science ®Google Scholar
• Hall JE. Guyton and Hall Textbook of Medical Physiology, 12th edn. Philadelphia: Saunders Elsevier, 2010
   Google Scholar
• Cubeddu LX. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Am Heart J 1988;116(1 Pt 1):133-62
   PubMed Web of Science ®Google Scholar
• Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001;58:508-16
   PubMed Web of Science ®Google Scholar
• de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol 1998;34(Suppl 2):18-28, discussion 47
   Web of Science ®Google Scholar
• Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003;92:47-57M
   PubMed Web of Science ®Google Scholar
• Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000;18:1865-9
   Google Scholar
• Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83:21C-28C
   PubMed Web of Science ®Google Scholar
• Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999;83:576-82, A7
   PubMed Web of Science ®Google Scholar
• Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606-11
   PubMedGoogle Scholar
• Nieminen T, Tammela TL, Koobi T, et al. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 2006;176(6 Pt 1):2551-6
   PubMed Web of Science ®Google Scholar
• Auerbach SM, Gittelman M, Mazzu A, et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64:998-1003, discussion 3-4
   PubMed Web of Science ®Google Scholar
• Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996;52:883-98
   PubMed Web of Science ®Google Scholar